76 / 89
76
67.
Nguyen VA, Eisendle K, Gruber I, Hugl B,
Reider D, Reider N. Effect of the dual
endothelin receptor antagonist bosentan on
Raynaud's phenomenon secondary to systemic
sclerosis:
a
double-blind
prospective,
randomized, placebo-controlled pilot study.
Rheumatology (Oxford) 2010;49:583-7.
68.
Gliddon AE, Doré CJ, Black CM, McHugh N,
Moots R, Denton CP, et al. Prevention of
vascular
damage
in
scleroderma
and
autoimmune
Raynaud's
phenomenon:
a
multicenter,
randomized,
double-blind,
placebo-controlled trial of the angiotensin-
converting enzyme inhibitor quinapril. Arthritis
Rheum 2007;56:3837-46.
69.
Dziadzio M, Denton CP, Smith R, Howell K,
Blann A, Bowers E, et al. Losartan therapy for
Raynaud's phenomenon and scleroderma:
clinical and biochemical findings in a fifteen-
week, randomized, parallel-group, controlled
trial. Arthritis Rheum 1999;42:2646-55.
70.
Shenoy PD, Kumar S, Jha LK, Choudhary SK,
Singh U, Misra R, et al. Efficacy of tadalafil in
secondary Raynaud's phenomenon resistant to
vasodilator therapy: a double-blind randomized
cross-over trial. Rheumatology (Oxford)
2010;49:2420-8.
71.
Schiopu E, Hsu VM, Impens AJ, Rothman JA,
McCloskey DA, Wilson JE, et al. Randomized
placebo-controlled crossover trial of tadalafil in